Ticarcillin/clavulanic acid

If the patient has been hospitalized in the last 6 months, has a urinary catheter, or is in a nursing home, the possibility of P. aeruginosa and enterococci infection, as well as multiply-resistant organisms, should be considered. In this setting, ceftazidime, ticarcillin-clavulanic acid, piperacillin, aztreonam, meropenem, or imipenem, in combination with an... 

Antipseudomonal penicillin piperacillin, piperacillin/tazobactam, ticarcillin/clavulanic acid. 

Current commercial inhibitors of /3-lactamases include clavulanic acid (an oxapenam see Table 1), sulbactam, and tazobactam (two penam sulfones see Table 1). They are effective only against the class A serine /3-lactamases and they are administrated in the form of antibiotic/inhibitor combinations <2006BP930> Augmentin (amoxicillin/clavulanic acid), Timentin (ticarcillin/clavulanic acid), Unasyn (ampicillin/Sulbactam), Zosyn (piperacillin/tazobactam). 

Ticarcillin + clavulanic acid, which is only used intravenously, has also been reported to induce a similar syndrome (33,34) and can also aggravate pre-existing hepatitis (35). One cholestatic reaction has been reported with intravenous sulbactam + ampicillin (36). 

Van der Auwera P, Legrand JC. Ticarcillin-clavulanic acid therapy in severe infections. Drugs Exp CUn Res 1985 11(11) 805-13. 

Piperacillin/tazobactam (PT) Ticarcillin/clavulanic acid (TQ Ampicillin/sulbactam (AS) Amoxicillin/clavulanic acid (AQ... 

Jacobs RF, Trang JM, Kearns GL, et al. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. J Pediatr 1985 106 1001-1007. 

Intra-abdominal infection— For intra-abdominal or pelvic infections likely to involve anaerobes, treatment should include either ticarcillin/clavulanic acid, ampicillin/sui-bactam, piperacillin/tazobactam, imipenem, mero-... 

Imipenem or meropenem amoxicillin/clavulanic acid ticarcillin/clavulanic acid piperacillin/tazobactam ampicillin/sulbactam cefoxitin cefotetan chloramphenicol cefmetazole penicillin G gatifloxacin or moxifloxacin Gentamicin... 

A fluoroquinolone a tetracycline gentamicin A fluoroquinolone amikacin a tetracycline trimethoprim-sulfamethoxazole cefotaxime, ceftizoxime, ceftriaxone, cefepime, or ceftazidime Gentamicin, tobramycin or amikacin trimethoprim-sulfamethoxazole ciprofloxacin, ticarcillin, mezlocillin, or piperacillin aztreonam cefotaxime ceftizoxime ceftriaxone cefepime or ceftazidime Ampicillin gentamicin, tobramycin, or amikacin carbenicillin, ticarcillin, mezlocillin, or piperacillin gentamicin, tobramycin, or amikacin amoxicillin/clavulanic acid ticarcillin/clavulanic acid piperacillin/tazobactam ampicillin/sulbactam trimethoprim-sulfamethoxazole imipenem or meropenem aztreonam a fluoroquinolone another cephalosporin... 

No interaction normalfy occurs between digoxin and amoxicillin, cefazolin, cefuroxime, flucloxacillin, phenoxymethylpenicillin or ticarcillin/clavulanic acid. No pharmacokinetic interaction occurs between ampicillin and digitoxin. In contrast, one early study found that cefradine increased serum levels of digoxin. 

Semisynthetic penicillins such as ampicillin, carbenicillin have a broader spectrum. Some, such as methicillin, oraficillin, and oxacillin, are resistant to penicillinase. In 1984, Beechem introduced Augmentin, which was the first combination formulation of a penicillin (amoxillin) and a penicillinase inhibitor (clavulanic acid). In 1985, Beechem introduced Timentin, a ticarcillin/clavulanic acid combination, and Pfizer in 1987 introduced Unasyn, an ampicillin/sulbactam sodium combination. 

---